Antibody variable domains and antibodies having decreased immunogenicity
Antibody variable domains with reduced ADA binding address the issue of immunogenicity in therapeutic proteins, enhancing safety and efficacy by minimizing ADA interactions.
HK40135080APending Publication Date: 2026-07-17NUMAB THERAPEUTICS AG
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- NUMAB THERAPEUTICS AG
- Filing Date
- 2026-04-21
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing antibodies used in therapeutic proteins exhibit high immunogenicity due to binding with anti-drug antibodies (ADAs), leading to reduced efficacy and safety concerns.
Method used
Development of antibody variable domains with reduced binding to ADAs, along with methods for generating and encoding these domains and antibodies, and their use in pharmaceutical compositions.
Benefits of technology
The solution reduces immunogenicity and enhances the safety and efficacy of therapeutic proteins by minimizing ADA binding, thereby improving therapeutic outcomes.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000140_0000 
Figure 00000141_0000 
Figure 00000141_0001
Abstract
The present invention relates to antibody variable domains, which exhibit a reduced binding to anti-drug antibodies (ADA), to antibodies comprising one or more of said antibody variable domains, and to pharmaceutical compositions comprising said antibodies. The present invention further relates to nucleic acids encoding said antibody variable domains or said antibodies, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said antibody variable domains or said multispecific antibodies. Additionally, the present invention relates to a method for generating said antibody variable domains and antibodies.
Need to check novelty before this filing date? Find Prior Art